Oslo, Norway

Kjell Eric Agner

This inventor holds 1 USPTO granted patent. Top assignee: Nycomed Imaging as. Active years: 1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kjell Eric Agner. Retrieved from https://idiyas.com/inventor/kjell-eric-agner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kjell Eric Agner: Innovator in Biochemistry

Introduction

Kjell Eric Agner is a notable inventor based in Oslo, Norway. He has made significant contributions to the field of biochemistry, particularly through his innovative patent.

Latest Patents

Kjell Eric Agner holds a patent for a compound titled "Disulphide-cyclo-βH-Cys-Glu-Gln-Tyr-Cys-OH!" This invention showcases his expertise in developing biochemical compounds with potential applications in various medical fields.

Career Highlights

Agner is currently associated with Nycomed Imaging AS, a company known for its advancements in medical imaging technologies. His work at Nycomed Imaging AS reflects his commitment to enhancing healthcare through innovative solutions.

Collaborations

Throughout his career, Agner has collaborated with esteemed colleagues, including Lars Orning and Kjell Steinar Sakariassen. These partnerships have contributed to the advancement of his research and innovations.

Conclusion

Kjell Eric Agner's contributions to biochemistry and his innovative patent highlight his role as a significant figure in the field. His work continues to influence advancements in medical technology and research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…